Objective: To assess the impact of long-term antiretroviral therapy (ART) on human immunodeficiency virus (HIV) blood screening outcomes in post-exposure prophylaxis (PEP) failure cases through a longitudinal analysis of blood screening results over a 7-year period in a patient with HIV PEP failure. Methods: This study conducted 13 follow-up assessments for a high-risk individual who initiated ART shortly after exposure. The effectiveness of various blood screening methods, including immunological assays and nucleic acid testing (NAT), was analyzed. Blood samples were also tested with HIV RNA quantification testing, Western blot (WB) confirmation testing, chemiluminescence immunoassay (CLIA), and HIV rapid tests utilizing gold and selenium labels. A comprehensive analysis was performed to evaluate the changes in diagnostic capabilities of different testing methods for HIV biomarkers over an extended period following PEP failure. Results: The patient had two high-risk exposures: one day before ART initiation (BA1) and seven days preceding treatment (BA7). On the first day after the ART treatment (AA1), the HIV RNA concentration (viral load) was 9.07×10 copies/mL; by day five (AA5), the viral load decreased to 1.04×10 copies/mL. At day eleven (AA11), NAT and ELISA tests were both positive, with the WB result remaining indeterminate (gp160+). At day 48 (AA48), the S/CO value of the fourth generation ELISA reagent was 1.07, while results from a 6-sample pool and quantitative NAT were negative. However, a single sample NAT returned a positive result and WB tests indicated positivity for p17, p24, and gp160. At AA74, the quantitative NAT rebounded to 2.83×10 copies/mL, with positive NAT results for single and 6-sample pool NAT tests. The S/CO values of the imported and domestic ELISA reagents were 3.39 and 23.44, respectively. At AA201, 6-sample pool and quantitative NAT were negative again, while single sample NAT remained positive. From AA319 to AA2221, all NAT results have remained consistently below the minimum detection limit. At AA2221, S/CO values of the imported and domestic ELISA reagents were 3.47 and 23.44, respectively. Conclusion: The findings indicate that patients experiencing PEP failure after high-risk HIV exposure are at a higher risk of being missed by mixed-sample NAT pools and individual serological tests. Nonetheless, anti-HIV antibody levels are sustained at elevated values for an extended duration, underscoring antibody testing as an effective measure for blood screening.

Background Asthma poses a serious threat to children's growth, development, and mental health, thus there has been an increasing focus on the control of asthma morbidity in children and the assessment of its risk factors. A growing body of research has found that exposure to ambient air pollutants an significatly increase the risk of childhood asthma. Objective To understand the changes of ambient air pollutant concentrations in Nanjing and asthma outpatient visits to Nanjing Children's Hospital, and to quantitatively analyze the effects of exposure to different ambient air pollutants on children's asthma outpatient visits. Methods Daily data of ambient air pollutants fine particulate matter (PM_2.5), inhalable particle (PM₁₀), sulfur dioxide (SO₂), nitrogen dioxide (NO₂), carbon monoxide (CO), ozone (O₃), meteorological factors (air temperature & relative humidity), and outpatient visits due to asthma in the hospital from January 1, 2019 to December 31, 2023 were collected, and a generalized additive model based on quasi poisson distributions was used to quantitatively analyze the short-term effects of ambient air pollutant exposure on outpatient visits due to asthma in the hospital. Results The annual average concentrations of PM_2.5, PM₁₀, SO₂, and NO₂ in Nanjing from 2019 to 2023 did not exceed the national limits. For single-day lagged effects, the single-pollutant model showed that the effects of PM_2.5, PM₁₀, NO₂, and CO on children's asthma outpatient visits were greatest for every 10 units increase at lag0, with excess risk (ER) of 1.39% (95%CI: 0.65%, 2.14%), 1.46% (95%CI: 0.97%, 1.95%), 5.46% (95%CI: 4.36%, 6.57%), and 0.18% (95%CI: 0.11%, 0.26%), respectively, and SO₂ reached the maximum effect at lag1, with an ER of 23.15% (95%CI: 13.57%, 33.53%) for each 10 units increase in concentration. Different pollutants reached their maximum cumulative lag effects at different time. The PM₁₀, PM_2.5, SO₂, NO₂, and CO showed the largest cumulative lag effects at lag01, lag01, lag02, lag02, and lag03, respectively, with ERs of 1.35% (95%CI: 0.77%, 1.92%), 0.96% (95%CI: 0.10%, 1.83%), 28.50% (95%CI: 15.49%, 42.98%), 6.92% (95%CI: 5.53%, 8.33%), and 0.31% (95%CI: 0.20%, 0.42%), respectively. The influences of PM_2.5 and PM₁₀ on outpatient visits due to asthma in the hospital became more pronounced with advancing age, while the associations with NO₂, SO₂, and CO were weakened as children grew older. Conclusion Ambient air pollutants (PM_2.5, PM₁₀, SO₂, NO₂, CO) can increase childhood asthma visits, and different pollutants have varied effects on the number of asthmatic children's visits at different ages.

Existing emotion recognition research is typically limited to static laboratory settings and has not fully handle the changes in emotional states in dynamic scenarios. To address this problem, this paper proposes a method for dynamic continuous emotion recognition based on electroencephalography (EEG) and eye movement signals. Firstly, an experimental paradigm was designed to cover six dynamic emotion transition scenarios including happy to calm, calm to happy, sad to calm, calm to sad, nervous to calm, and calm to nervous. EEG and eye movement data were collected simultaneously from 20 subjects to fill the gap in current multimodal dynamic continuous emotion datasets. In the valence-arousal two-dimensional space, emotion ratings for stimulus videos were performed every five seconds on a scale of 1 to 9, and dynamic continuous emotion labels were normalized. Subsequently, frequency band features were extracted from the preprocessed EEG and eye movement data. A cascade feature fusion approach was used to effectively combine EEG and eye movement features, generating an information-rich multimodal feature vector. This feature vector was input into four regression models including support vector regression with radial basis function kernel, decision tree, random forest, and K-nearest neighbors, to develop the dynamic continuous emotion recognition model. The results showed that the proposed method achieved the lowest mean square error for valence and arousal across the six dynamic continuous emotions. This approach can accurately recognize various emotion transitions in dynamic situations, offering higher accuracy and robustness compared to using either EEG or eye movement signals alone, making it well-suited for practical applications.
Humans ; Electroencephalography/methods* ; Emotions/physiology* ; Eye Movements/physiology* ; Signal Processing, Computer-Assisted ; Support Vector Machine ; Algorithms

Current studies on electroencephalogram (EEG) emotion recognition primarily concentrate on discrete stimulus paradigms under controlled laboratory settings, which cannot adequately represent the dynamic transition characteristics of emotional states during multi-context interactions. To address this issue, this paper proposes a novel method for emotion transition recognition that leverages a cross-modal feature fusion and global perception network (CFGPN). Firstly, an experimental paradigm encompassing six types of emotion transition scenarios was designed, and EEG and eye movement data were simultaneously collected from 20 participants, each annotated with dynamic continuous emotion labels. Subsequently, deep canonical correlation analysis integrated with a cross-modal attention mechanism was employed to fuse features from EEG and eye movement signals, resulting in multimodal feature vectors enriched with highly discriminative emotional information. These vectors are then input into a parallel hybrid architecture that combines convolutional neural networks (CNNs) and Transformers. The CNN is employed to capture local time-series features, whereas the Transformer leverages its robust global perception capabilities to effectively model long-range temporal dependencies, enabling accurate dynamic emotion transition recognition. The results demonstrate that the proposed method achieves the lowest mean square error in both valence and arousal recognition tasks on the dynamic emotion transition dataset and a classic multimodal emotion dataset. It exhibits superior recognition accuracy and stability when compared with five existing unimodal and six multimodal deep learning models. The approach enhances both adaptability and robustness in recognizing emotional state transitions in real-world scenarios, showing promising potential for applications in the field of biomedical engineering.
Humans ; Emotions/physiology* ; Electroencephalography ; Neural Networks, Computer ; Eye Movements ; Perception

Background:To compare the efficacy and safety of monthly administrations of gonadotropin releasing hormone (GnRH) agonists LY01005 and Zoladex ? in Chinese patients with premenopausal breast cancer. Methods:From October 2020 to November 2021, 188 premenopausal breast cancer patients were enrolled in 34 hospitals and randomized 1:1 to receive either LY01005 or Zoladex ? every 28 days for a total of three injections. All patients concomitantly received oral tamoxifen (TAM). The primary efficacy endpoint was cumulative probability of maintaining menopausal level [oestradiol (E2) ≤30 pg/ml] from day 29 to day 85. The second efficacy endpoint included changes in E2, luteinizing hormone (LH), and follicle-stimulating hormone (FSH) compared with the baseline. Pharmacokinetics (PK), pharmacodynamics (PD), and safety were analyzed. The study also evaluated the pharmacokinetic and pharmacodynamic characteristics of LY01005. Results:A total of 188 patients were randomised and 187 patients received either LY01005 or Zoladex ?. Cumulative probabilities of maintaining menopausal level (E2≤30 pg/ml) from day 29 to day 85 were 93.1% for LY01005 and 86.3% for Zoladex ?. The between-group difference was 6.8% (95% CI: -2.3%, 15.9%) and primary efficacy in the LY01005 group was not inferior to that in the Zoladex ? group. Changes in E2, LH, and FSH levels compared with the baseline were equivalent between the two groups (E2: 89.34% to 90.23% vs. 82.11% to 85.02%; LH: 88.89% to 95.52% vs. 89.70% to 97.02%; FSH: 75.36% to 80.85% vs.73.07% to 80.24%, respectively). After three consecutive doses of LY01005, the LH and FSH levels of the subjects showed a transient increase after the first dose, reached a peak on the second day and then started to decrease. The LH and FSH reached a lower level and remained at or below that level until the 85th day. Both treatments were well-tolerated. Conclusion:LY01005 is as effective as Zoladex ? in suppressing E2 to menopausal levels in Chinese patients with premenopausal breast cancer, with a similar safety profile.

Background:To compare the efficacy and safety of monthly administrations of gonadotropin releasing hormone (GnRH) agonists LY01005 and Zoladex ? in Chinese patients with premenopausal breast cancer. Methods:From October 2020 to November 2021, 188 premenopausal breast cancer patients were enrolled in 34 hospitals and randomized 1:1 to receive either LY01005 or Zoladex ? every 28 days for a total of three injections. All patients concomitantly received oral tamoxifen (TAM). The primary efficacy endpoint was cumulative probability of maintaining menopausal level [oestradiol (E2) ≤30 pg/ml] from day 29 to day 85. The second efficacy endpoint included changes in E2, luteinizing hormone (LH), and follicle-stimulating hormone (FSH) compared with the baseline. Pharmacokinetics (PK), pharmacodynamics (PD), and safety were analyzed. The study also evaluated the pharmacokinetic and pharmacodynamic characteristics of LY01005. Results:A total of 188 patients were randomised and 187 patients received either LY01005 or Zoladex ?. Cumulative probabilities of maintaining menopausal level (E2≤30 pg/ml) from day 29 to day 85 were 93.1% for LY01005 and 86.3% for Zoladex ?. The between-group difference was 6.8% (95% CI: -2.3%, 15.9%) and primary efficacy in the LY01005 group was not inferior to that in the Zoladex ? group. Changes in E2, LH, and FSH levels compared with the baseline were equivalent between the two groups (E2: 89.34% to 90.23% vs. 82.11% to 85.02%; LH: 88.89% to 95.52% vs. 89.70% to 97.02%; FSH: 75.36% to 80.85% vs.73.07% to 80.24%, respectively). After three consecutive doses of LY01005, the LH and FSH levels of the subjects showed a transient increase after the first dose, reached a peak on the second day and then started to decrease. The LH and FSH reached a lower level and remained at or below that level until the 85th day. Both treatments were well-tolerated. Conclusion:LY01005 is as effective as Zoladex ? in suppressing E2 to menopausal levels in Chinese patients with premenopausal breast cancer, with a similar safety profile.

OBJECTIVE To investigate the reference range of tacrolimus blood concentration in children with Henoch-Schonlein purpura nephritis(HSPN)and analyze the factors affecting the blood concentration,in order to provide a reference for rational use of the drug in clinic.METHODS Clinical data of children with HSPN who were treated with tacrolimus and regularly monitored for blood concentration at the Children's Hospital Affiliated to Kunming Medical University were retrospectively collected from January 2018 to January 2024.The threshold of effective concentration of tacrolimus was determined by the receiver operating characteristic curve of the subjects.The clinical efficacy of tacrolimus in different concentrations and the incidence of adverse drug reaction(ADR)were compared to determine the reference range of tacrolimus blood concentration.The factors influencing the blood concentration were analyzed by one-way and multiple linear regression.RESULTS A total of 97 pediatric patients were included,and their tacrolimus blood concentrations were monitored 203 times,the blood concentration was 4.26(2.47,6.34)ng/mL.The area under the receiver operating characteristic curve of the subjects was 0.723(95%CI:0.596-0.850,P＜0.01),which corresponded to an effective threshold of 2.19 ng/mL.The clinical efficacy in pediatric patients with tacrolimus blood concentrations of 3-＜5 ng/mL,5-＜10 ng/mL,and≥10 ng/mL was significantly higher than that of children with concentrations＜3 ng/mL(P＜0.05).Additionally,the overall incidence of ADR in children with concentrations of 5-＜10 ng/mL and≥10 ng/mL was significantly higher than that in children with concentrations＜3 ng/mL and 3-＜5 ng/mL(P＜0.05).The impact of body mass index and CYP3A5 genotype on the blood concentration of tacrolimus was statistically significant(P＜0.05).CONCLUSIONS When using tacrolimus to treat HSPN in children clinically,the reference range for blood concentration is 3 to 5 ng/mL;body mass index and CYP3A5 genotype are factors that influence the blood concentration of tacrolimus.

Objective: To systematically evaluate the willingness to receive influenza vaccines among Chinese medical staff, so as to provide the evidence for developing the influenza vaccination strategy and improving the coverage of influenza vaccination among medical staff. Methods: Publications pertaining to the willingness to receive influenza vaccines among Chinese medical staff were retrieved from international and national databases from January 1, 2010 to October 1, 2023, including CNKI, Wanfang Data, VIP, SinoMed, PubMed, Web of Science and Embase. A meta-analysis was performed using the software Stata 17.0, sensitivity analysis was performed using the leave-one-out method, and the publication bias was evaluated using Funnel plot. Results: Totally 674 publications were retrieved, and 17 case-control studies were finally enrolled, with 23 697 participants. Meta-analysis showed that the rate of willingness to receive influenza vaccines among medical staff in China was 52.8% (95%CI: 41.3%-64.4%). The rates of willingness to receive influenza vaccines were 40.2% (95%CI: 28.5%-51.8%) in 2019 and before and 67.2% (95%CI: 56.5%-77.9%) in 2020 and beyond; 54.6% (95%CI: 44.2%-65.0%) in men and 56.8% (95%CI: 49.3%-64.4%) in women; 53.6% (95%CI: 40.9%-66.2%) in doctors, 53.9% (95%CI: 41.0%-66.8%) in nurses, 62.8% (95%CI: 46.2%-79.3%) in technicians and 53.1% (95%CI: 36.1%-70.0%) in administrative and logistical staff; 77.4% (95%CI: 63.7%-91.2%) and 43.3% (95%CI: 30.5%-56.1%) in staff with and without a history of influenza vaccination; 49.8% (95%CI: 27.3%-72.3%) and 58.3% (95%CI: 43.9%-72.6%) in studies with a sample size of <1 000 and ≥1 000, and these differences were statistically significant (all P<0.05). Sensitivity analysis showed robustness of results, and Funnel plot showed publication bias. Conclusion The rates of willingness to receive influenza vaccines among medical staff in China ranged from 41.3% to 64.4%, and were lower in studies in 2019 and before, in men, in administrative and logistical staff and in staff without a history of influenza vaccination.

【Objective】 To explore the the potential risks of antiretroviral therapy(ART) drugs on blood safety among blood donors in Shenzhen. 【Methods】 High pressure liquid chromatography coupled with tandem mass spectrometry (HPLC-MS/MS) was used to measure ART drugs concentrations in the plasma of regular blood donors (negative control group, n=86) and anti-HIV positive individuals (experimental group, n=98, detected from approximately 440 000 blood donors during 2019—2023). The baseline plasma concentrations of ART drugs in the negative control group were clarified, and the impact of ART drugs on blood safety was analyzed. 【Results】 The baseline concentrations of ART drugs were not detected in 86 samples of negative control group. Four positive ART drugs samples were detected in 1∶2 pooled plasma samples of 98 anti-HIV positive blood donors plasma in the resolution test. The ART positive rate of anti-HIV positive donors was 4.08%, with tenofovir, lamivudine and efavirenz detected in three blood donors and lamivudine, lopinavir, ritonavir and zidovudine detected in one blood donor. 【Conclusion】 ART drugs were found among anti-HIV positive blood donors in Shenzhen. Additional research is needed to investigate the motivation of these specific donors, so as to ascertain the groups most susceptible to potential risks, and guarantee blood safety.

Alzheimer's disease (AD) is a leading cause of dementia in the elderly. Mitogen-activated protein kinase phosphatase 1 (MKP-1) plays a neuroprotective role in AD. However, the molecular mechanisms underlying the effects of MKP-1 on AD have not been extensively studied. MicroRNAs (miRNAs) regulate gene expression at the post-transcriptional level, thereby repressing mRNA translation. Here, we reported that the microRNA-429-3p (miR-429-3p) was significantly increased in the brain of APP23/PS45 AD model mice and N2A^APP AD model cells. We further found that miR-429-3p could downregulate MKP-1 expression by directly binding to its 3'-untranslated region (3' UTR). Inhibition of miR-429-3p by its antagomir (A-miR-429) restored the expression of MKP-1 to a control level and consequently reduced the amyloidogenic processing of APP and Aβ accumulation. More importantly, intranasal administration of A-miR-429 successfully ameliorated the deficits of hippocampal CA1 long-term potentiation and spatial learning and memory in AD model mice by suppressing extracellular signal-regulated kinase (ERK1/2)-mediated GluA1 hyperphosphorylation at Ser831 site, thereby increasing the surface expression of GluA1-containing α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs). Together, these results demonstrate that inhibiting miR-429-3p to upregulate MKP-1 effectively improves cognitive and synaptic functions in AD model mice, suggesting that miR-429/MKP-1 pathway may be a novel therapeutic target for AD treatment.